Topic: International Drug Pricing

  • Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019

  • US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light

  • DPL responds to HHS Blueprint (May 16, 2018)

  • R&D Costs Do Not Explain Elevated U.S. Drug Prices